KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 170 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,364 | -25.1% | 6,242 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $11,173 | -32.7% | 6,242 | +46.2% | 0.00% | 0.0% |
| Q1 2023 | $16,610 | +5.7% | 4,270 | -7.6% | 0.00% | 0.0% |
| Q4 2022 | $15,715 | -37.7% | 4,622 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $25,236 | +110.5% | 4,622 | +73.9% | 0.00% | 0.0% |
| Q2 2022 | $11,988 | -66.2% | 2,658 | -44.8% | 0.00% | 0.0% |
| Q1 2022 | $35,464 | -57.5% | 4,812 | -62.9% | 0.00% | 0.0% |
| Q4 2021 | $83,461 | +24.3% | 12,980 | +12.5% | 0.00% | 0.0% |
| Q3 2021 | $67,134 | -70.8% | 11,535 | -48.2% | 0.00% | -66.7% |
| Q2 2021 | $229,589 | +12.7% | 22,247 | +14.9% | 0.00% | 0.0% |
| Q1 2021 | $203,730 | -39.5% | 19,366 | -10.9% | 0.00% | -40.0% |
| Q4 2020 | $336,535 | +6.0% | 21,740 | 0.0% | 0.01% | -16.7% |
| Q3 2020 | $317,404 | -22.9% | 21,740 | 0.0% | 0.01% | -14.3% |
| Q2 2020 | $411,756 | +17.4% | 21,740 | +19.1% | 0.01% | 0.0% |
| Q1 2020 | $350,775 | -10.9% | 18,260 | -11.1% | 0.01% | 0.0% |
| Q4 2019 | $393,848 | +92.0% | 20,545 | -3.6% | 0.01% | +133.3% |
| Q3 2019 | $205,079 | +636.4% | 21,318 | +358.6% | 0.00% | – |
| Q2 2019 | $27,847 | -81.7% | 4,649 | -71.4% | 0.00% | -100.0% |
| Q4 2018 | $152,497 | -45.0% | 16,275 | 0.0% | 0.00% | -40.0% |
| Q3 2018 | $277,163 | -99.9% | 16,275 | 0.0% | 0.01% | +25.0% |
| Q2 2018 | $276,512,000 | +75.8% | 16,275 | +38.9% | 0.00% | +100.0% |
| Q1 2018 | $157,269,000 | +146880.4% | 11,719 | +4.8% | 0.00% | +100.0% |
| Q4 2017 | $107,000 | -55.6% | 11,177 | -49.0% | 0.00% | -50.0% |
| Q3 2017 | $241,000 | +21.7% | 21,911 | 0.0% | 0.00% | +100.0% |
| Q2 2017 | $198,000 | -29.5% | 21,911 | 0.0% | 0.00% | -50.0% |
| Q1 2017 | $281,000 | +36.4% | 21,911 | 0.0% | 0.00% | +100.0% |
| Q4 2016 | $206,000 | +9.0% | 21,911 | +12.6% | 0.00% | 0.0% |
| Q3 2016 | $189,000 | +39.0% | 19,451 | -3.8% | 0.00% | 0.0% |
| Q2 2016 | $136,000 | -39.3% | 20,210 | +19.4% | 0.00% | -50.0% |
| Q4 2015 | $224,000 | +25.8% | 16,920 | 0.0% | 0.00% | +100.0% |
| Q3 2015 | $178,000 | -61.3% | 16,920 | 0.0% | 0.00% | -66.7% |
| Q2 2015 | $460,000 | +25.3% | 16,920 | +72.8% | 0.00% | 0.0% |
| Q4 2014 | $367,000 | +7.3% | 9,793 | 0.0% | 0.00% | +50.0% |
| Q3 2014 | $342,000 | -25.0% | 9,793 | 0.0% | 0.00% | -33.3% |
| Q2 2014 | $456,000 | +132.7% | 9,793 | +54.3% | 0.00% | +200.0% |
| Q1 2014 | $196,000 | -16.2% | 6,346 | -37.9% | 0.00% | -50.0% |
| Q4 2013 | $234,000 | – | 10,221 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $35,031,000 | 23.03% |
| Palo Alto Investors LP | 5,267,652 | $81,543,000 | 4.28% |
| Fairmount Funds Management LLC | 702,351 | $10,872,000 | 3.89% |
| Birchview Capital, LP | 188,000 | $2,910,000 | 1.68% |
| Mesirow Financial Investment Management, Inc. | 22,303 | $345,250,000 | 1.09% |
| EMERALD ADVISERS, LLC | 1,822,781 | $28,217,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,661,236 | $25,716,000 | 0.90% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,552,504 | $24,033,000 | 0.85% |
| Altium Capital Management LP | 133,951 | $2,074,000 | 0.77% |
| Hood River Capital Management LLC | 931,754 | $14,424,000 | 0.48% |